Clinical Trial Update: Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan and paclitaxel in metastatic or recurrent esophageal or gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED